| [1] |
Liu Jing, Liu Qin, Huang Mei.
Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm
[J]. Journal of International Oncology, 2024, 51(5): 267-273.
|
| [2] |
He Jiahui, Hu Qinyong.
Comparative analysis of lung cancer incidence and mortality trends and risk factors in China and the United States based on GBD data
[J]. Journal of International Oncology, 2024, 51(1): 29-36.
|
| [3] |
Zhao Xin, Fan Xuewu, Tian Long, Hu Yimin.
Application and evaluation study of 3D ultrasound in image guided radiotherapy for prostate cancer
[J]. Journal of International Oncology, 2024, 51(1): 43-49.
|
| [4] |
Deng Juanjun, Zhao Dayong, Li Miao.
Adverse reactions and risk factors of immune checkpoint inhibitors in the treatment of non-small cell lung cancer
[J]. Journal of International Oncology, 2023, 50(9): 564-568.
|
| [5] |
Zhang Jinnan, Liu Bangqing, Li Jun, Liu Xiaohui.
Research on BHLHE40 targets HMGA2 to reduce the sensitivity of thyroid cancer cells to cisplatin through activating the oxidative phosphorylation pathway
[J]. Journal of International Oncology, 2023, 50(7): 398-406.
|
| [6] |
Zhao Qianwen, Peng Danli, Qin Tao, Mao Guofei, Tang Hui, Yang Jun.
Analysis of global cancer incidence and mortality from 1990 to 2019
[J]. Journal of International Oncology, 2023, 50(7): 425-431.
|
| [7] |
Yang Lirong, Wang Yufeng.
Construction of machine learning models for predicting the risk of postoperative distant metastasis recurrence in serous ovarian cancer
[J]. Journal of International Oncology, 2023, 50(4): 220-226.
|
| [8] |
Jiao Panpan, Xue Lijuan, Zhan Juan.
Risk factors and predictors of immune-related adverse events induced by immune checkpoint inhibitors
[J]. Journal of International Oncology, 2023, 50(12): 739-744.
|
| [9] |
Yang Sha, Yang Xiaohua, Wang Suhua, Xue Xiaoyan, Xu Jun.
Analysis of risk factors for deep vein thrombosis of lower extremity after thoracoscopic surgery for elderly lung cancer and establishment and validation of prediction model
[J]. Journal of International Oncology, 2022, 49(9): 532-536.
|
| [10] |
Zhang Yan, Pan Lei, Liu Shuting.
Establishment of an efficacy prediction model for gefitinib in non-small cell lung cancer patients based on ABCB1 and ABCG2 gene polymorphisms
[J]. Journal of International Oncology, 2022, 49(6): 327-333.
|
| [11] |
Zhu Yishuo, Cui Yujie, Liu Qi, Li Jun, Fan Yuechao.
Analysis of risk factors and prediction model establishment for early postoperative recurrence in glioma patients
[J]. Journal of International Oncology, 2022, 49(2): 79-83.
|
| [12] |
Li Jinhao, Wang Guidong, Li Xuefei, Liu Zilin, Meng Kailong.
Clinical study of venous phase CT value in predicting central group lymph node metastasis of papillary thyroid carcinoma
[J]. Journal of International Oncology, 2022, 49(10): 581-585.
|
| [13] |
Duan Shuai, Guo Chenming, Li Huifang, Dilimulati · Aisimutula.
Trends in incidence and mortality of female breast cancer in China from 1990 to 2019 and age-period-cohort model analysis
[J]. Journal of International Oncology, 2022, 49(10): 586-591.
|
| [14] |
Wu Yuping, Zhang Xiaoyu, Lu Keyi.
Mechanism of PD-L1 in thyroid carcinoma and its application in diagnosis and treatment
[J]. Journal of International Oncology, 2021, 48(9): 560-563.
|
| [15] |
Feng Zhiping, Yang Chuanzhou, Chen Ting, Zhu Jialun, Liu Chao, Lyu Juan, Lu Jianmei, Deng Zhiyong.
BRD4 inhibitor specifically inhibits the development of wild-type Kras differentiated thyroid carcinoma by regulating BRD4/miR-106b-5p/P21 axis
[J]. Journal of International Oncology, 2021, 48(8): 463-472.
|
